F008 Managing Tough Real Life Dermatology Cases
DESCRIPTION
A faculty of experienced clinicians will present tough-to-manage real life patients, and how each was handled. The faculty is asked to focus on conditions that present to clinicians in private practice, and cases will span medical, surgical, and pediatric dermatology-- there will be something for everyone. We use an audience response system and encourage interaction between the audience and faculty. This activity has been approved by the American Board of Dermatology (ABD) for up to 20 Continuous Certification Program (CCP) Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org.
LEARNING OBJECTIVES
Recognize key diagnostic features of challenging disorders.
Manage tough-to-treat disorders.
Consider alternative treatment modalities.
DIRECTOR
Anthony Fernandez, MD, FAAD
SPEAKERS
Jeffrey Phillip Callen, MD, FAAD
Dirk Michael Elston, MD, FAAD
Andrea Maderal, MD, FAAD
Melissa Piliang, MD, FAAD
Samantha A Polly, MD, FAAD
Christine Baran Warren, MS, MD, FAAD
DISCLOSURES
Jeffrey Phillip Callen, MD, FAAD
3M Pharmaceuticals – Stockholder Public Company(No Compensation Received); Abbott Laboratories – Stockholder Public Company(No Compensation Received); AbbVie – Stockholder Public Company(No Compensation Received); Allergan, Inc – Stockholder Public Company(No Compensation Received); Amgen – Stockholder Public Company(No Compensation Received); Biogen – Data Safety Monitoring Board(Honoraria); Celgene – Stockholder Public Company(No Compensation Received); Elsevier Inc. – Other(Other Financial Benefit); JAMA – Other(No Compensation Received); Johnson and Johnson – Stockholder Public Company(No Compensation Received); Merck & Co., Inc – Stockholder Public Company(No Compensation Received); Pfizer Inc. – Stockholder Public Company(No Compensation Received); Procter & Gamble Company – Stockholder Public Company(No Compensation Received); Proivant – Data Safety Monitoring Board(Fees); UpToDate, Inc. – Other(Honoraria);
Dirk Michael Elston, MD, FAAD
No financial relationships exist with ineligible companies.
Anthony Fernandez, MD, FAAD
Amgen – Speaker(Honoraria); Astra Zeneca – Investigator(Grants/Research Funding); Biogen – Advisory Board(Honoraria), Consultant(Honoraria); Boehringer Ingelheim – Investigator(Grants/Research Funding); Castle Biosciences, Inc – Investigator(Grants/Research Funding); EMD Serono – Investigator(Grants/Research Funding); Galderma – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Incyte – Investigator(Grants/Research Funding); Johnson & Johnson – Advisory Board(Honoraria); Mallinckrodt Pharmaceuticals – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Merck & Co., Inc – Consultant (1099 relationship)(Honoraria); Pfizer Inc. – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Priovant – Investigator(Grants/Research Funding); Priovant Therapeutics – Advisory Board(Honoraria); Sanofi/Regeneron – Consultant (1099 relationship)(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); UCB – Consultant(Honoraria);
Andrea Maderal, MD, FAAD
argenx – Consultant (1099 relationship)(Fees); Biogen – Investigator(Other Financial Benefit); Johnson and Johnson – Advisory Board(Fees); Medicines Development for Global Health – Data Safety Monitoring Board(Honoraria);
Melissa Piliang, MD, FAAD
AbbVie – Advisory Board(Honoraria), Investigator(No Compensation Received); Eli Lilly and Company – Investigator(No Compensation Received), Speaker(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(No Compensation Received), Speaker(Honoraria); Procter & Gamble Company – Consultant(Honoraria); Sanofi – Investigator(No Compensation Received);
Samantha A Polly, MD, FAAD
No financial relationships exist with ineligible companies.
Christine Baran Warren, MS, MD, FAAD
UpToDate, Inc – Other(Patent royalties or other compensation for Intellectual Property Rights);